Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Dec 23, 2025
Reporting period
Not applicable
Filed with the SEC
Dec 30, 2025
ChairGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
None found in footnotes
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001140361-25-046788
Filed / recorded
Dec 30, 2025, 7:00 AM UTC
Added to OQRO
Oct 6, 2026, 8:46 PM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
Roivant Sciences Ltd.
Issuer CIK
1635088
Ticker
ROIV
Reporting person
Frank Torti
Relationship
Officer
Officer title
President and Vant Chair
Security
Common Shares
Table
Non-derivative (Table I)
Transaction date
Dec 23, 2025
Transaction code
A
Shares / units
175,380
Price per share
$22.45
Acquired / disposed
Acquired (A)
Shares owned after
13,911,927
Ownership form
Direct
Amendment
No
Footnotes from the filing
Represents Common Shares received in exchange for shares of a subsidiary of the Issuer. The per Common Share price represents the closing price of the Issuer's Common Shares on the date of the exchange.